Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.42-0.14 (-2.52%)
At close: 04:00PM EDT
5.70 +0.28 (+5.17%)
After hours: 06:31PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.56
Bid0.00 x 1200
Ask0.00 x 1800
Day's range5.38 - 5.61
52-week range4.02 - 43.12
Avg. volume4,185,264
Market cap534.918M
Beta (5Y monthly)1.52
PE ratio (TTM)N/A
EPS (TTM)-2.89
Earnings date02 May 2023 - 08 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.27
  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming March Investor Conferences

    SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: 43rd Annual TD Cowen Health Care Conference on Wednesday, March

  • Simply Wall St.

    Fate Therapeutics Full Year 2022 Earnings: Beats Expectations

    Fate Therapeutics ( NASDAQ:FATE ) Full Year 2022 Results Key Financial Results Revenue: US$96.3m (up 72% from FY 2021...

  • Zacks

    FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus

    FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.